N@N

Jay Olson Maintained (ACAD) at Hold with Increased Target to $17 on, Feb 15th, 2023

Jay Olson of Oppenheimer, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $16 to $17 on, Feb 15th, 2023.

Jay has made no other calls on ACAD in the last 4 months.

There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 4 agree with Jay's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $19 on, Tuesday, January 31st, 2023
• Uy Ear of "Mizuho" Maintained at Hold with Decreased Target to $15 on, Wednesday, December 21st, 2022
• Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
• Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022

These are the ratings of the 3 analyists that currently disagree with Jay

---

• Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023
• Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022
• Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $21 on, Thursday, November 3rd, 2022

Contributing Sources

---